Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 250 50 versus ANORO ELLIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 250 50 versus ANORO ELLIPTA.
ADVAIR DISKUS 250/50 vs ANORO ELLIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators. Salmeterol xinafoate is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by increasing cyclic AMP.
ANORO ELLIPTA is a combination of umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA). Umeclidinium inhibits acetylcholine at M3 receptors in bronchial smooth muscle, causing bronchodilation. Vilanterol stimulates beta2-adrenergic receptors, leading to relaxation of bronchial smooth muscle and increased cyclic AMP.
1 inhalation (fluticasone propionate 250 mcg and salmeterol 50 mcg) twice daily, approximately 12 hours apart, via oral inhalation.
One inhalation (umeclidinium 62.5 mcg / vilanterol 25 mcg) once daily, orally inhaled.
None Documented
None Documented
Fluticasone propionate: 14-17 hours (terminal). Salmeterol: 5.5 hours (terminal). The fluticasone half-life supports twice-daily dosing with potential accumulation.
Umeclidinium: 11 hours (terminal); vilanterol: 2.5 hours (terminal). Steady-state achieved by day 14 once-daily dosing.
Fluticasone propionate: <5% renal (as metabolites), majority biliary/fecal. Salmeterol: 57% renal (as metabolites), 30% fecal.
Umeclidinium: 0.7% unchanged in urine, 58% as metabolites in feces; vilanterol: 26% unchanged in urine, 70% as metabolites in feces. Total elimination: renal (30-40% for vilanterol metabolites) and fecal (primary).
Category C
Category C
Corticosteroid/LABA Combination
LAMA/LABA Combination